Takara Bio, Inc. engages in development and marketing of genetic engineering technologies. The company is headquartered in Kusatsu-Shi, Shiga-Ken and currently employs 1,779 full-time employees. The company went IPO on 2004-12-07. The firm operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
Follow-Up Questions
Takara Bio Inc 'in CEO'su kimdir?
Mr. Koichi Nakao 2007 'den beri şirketle birlikte olan Takara Bio Inc 'in President 'ıdır.
TKBIF hissesinin fiyat performansı nasıl?
TKBIF 'in mevcut fiyatı $0 'dir, son işlem günde 0% decreased etti.
Takara Bio Inc için ana iş temaları veya sektörler nelerdir?
Takara Bio Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Takara Bio Inc 'in piyasa değerlemesi nedir?
Takara Bio Inc 'in mevcut piyasa değerlemesi $NaN 'dir
Takara Bio Inc al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 5 analist Takara Bio Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 1 güçlü al, 3 al, 4 tut, 0 sat ve 1 güçlü sat içermektedir
